Psoriatic Arthritis Therapeutics Pipeline Analysis - Clinical Trials & Results, Collaboration and Other Developments

The number of drug candidates in pipeline for psoriatic arthritis are expected to increase on account of increase in the prevalence of psoriasis, globally. Psoriasis is the skin disease which is more common in Caucasian as compared to the African American and Asian Americans. The disease is symptomatized by white and scaly red patches. The prevalence of psoriatic arthritis has been increasing mainly in the patients, who are more susceptible to infection that may activate their immune system. Increase in mortality rate, other inflammatory disease complication and awareness regarding health issues are the main reasons, that are responsible for the growth of psoriatic arthritis therapeutics pipeline. According to the data published by National Institute of Health in 2014, the incidence of psoriatic arthritis ranged from 0.1 out of 100000 people in Japan to 23.1 out of 100000 people in Finland, in the Europe and America the prevalence of psoriatic arthritis varied from 0.02-0.42% of the total population. Indians have highest prevalence of psoriatic arthritis in, Singapore’s multi-ethnic population.

Explore Report at: https://www.psmarketresearch.com/market-analysis/psoriatic-arthritis-therapeutics-pipeline-analysis

Psoriatic arthritis is a chronic inflammatory disease which involves inflammation of skin, synovial tissue and usually gives seronegative results for rheumatoid factor. Other complex diseases which are associated with psoriatic arthritis include ankylosing spondylitis, arthritis associated with inflammatory bowel disease and reactive arthritis. The psoriatic arthritis is diagnoses is done on the basis of the medical or family history and physical examinations such as magnetic field resonance imaging and x-ray of the affected joints. Currently, researchers are looking for better ways to diagnose psoriatic arthritis accurately, since at times a lot of similarity exist between psoriatic arthritis and other inflammatory form of arthritis. Contrast-enhanced MRI has also been developed by the researchers that can differentiate between psoriatic arthritis and rheumatoid arthritis in hand and wrist.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/psoriatic-arthritis-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of Psoriatic arthritis therapeutics include Novartis AG, Amgen Plc, Galapagos NV, AbbVie, Inc., Pfizer, Inc., Celgene Corporation, Janssen Pharmaceutical K.K.